Harvest Fund Management Co. Ltd Buys Shares of 1,178 10x Genomics, Inc. (NASDAQ:TXG)

Harvest Fund Management Co. Ltd bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 1,178 shares of the company’s stock, valued at approximately $66,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. raised its position in shares of 10x Genomics by 51.6% in the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after acquiring an additional 266 shares in the last quarter. AIA Group Ltd raised its position in shares of 10x Genomics by 0.9% in the 4th quarter. AIA Group Ltd now owns 41,369 shares of the company’s stock worth $2,315,000 after acquiring an additional 365 shares in the last quarter. Xponance Inc. raised its position in shares of 10x Genomics by 3.2% in the 3rd quarter. Xponance Inc. now owns 13,060 shares of the company’s stock worth $539,000 after acquiring an additional 400 shares in the last quarter. Parametrica Management Ltd raised its position in shares of 10x Genomics by 3.4% in the 3rd quarter. Parametrica Management Ltd now owns 15,300 shares of the company’s stock worth $631,000 after acquiring an additional 500 shares in the last quarter. Finally, Mirador Capital Partners LP raised its position in shares of 10x Genomics by 1.9% in the 4th quarter. Mirador Capital Partners LP now owns 27,885 shares of the company’s stock worth $1,560,000 after acquiring an additional 521 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Stifel Nicolaus reduced their price target on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Barclays dropped their target price on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

Insider Activity

In other news, CEO Serge Saxonov sold 2,821 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $130,725.14. Following the completion of the transaction, the chief executive officer now owns 847,560 shares of the company’s stock, valued at approximately $39,275,930.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Benjamin J. Hindson sold 2,613 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $121,086.42. Following the completion of the transaction, the insider now owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 2,821 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $130,725.14. Following the completion of the transaction, the chief executive officer now directly owns 847,560 shares of the company’s stock, valued at approximately $39,275,930.40. The disclosure for this sale can be found here. Insiders sold a total of 12,959 shares of company stock valued at $592,806 in the last quarter. 10.65% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

10x Genomics stock opened at $26.90 on Friday. The business’s 50-day simple moving average is $38.12 and its two-hundred day simple moving average is $42.60. The company has a market cap of $3.21 billion, a PE ratio of -12.40 and a beta of 1.90. 10x Genomics, Inc. has a fifty-two week low of $26.30 and a fifty-two week high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). The firm had revenue of $183.98 million for the quarter, compared to analysts’ expectations of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.15) EPS. As a group, analysts predict that 10x Genomics, Inc. will post -1.47 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.